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• Menorrhagia is the presenting symptom for the majority of women who undergo a hysterectomy.
2,3
• While serious complications from menorrhagia are rare, patients' quality of life is significantly impacted by this condition.
4
• Treatment for menorrhagia can be pharmacological and/or surgical. Surgical treatments include uterine artery embolization, myomectomy, hysterectomy, first-generation endometrial ablation methods (rollerball or laser ablation and transcervical resection of endometrium), and second-generation endometrial ablation methods (laser intrauterine thermotherapy, cryoablation, and microwave, thermal balloon, or radiofrequency ablation).
• Endometrial ablation methods are very effective and have a low complication rate and high satisfaction rate, but there are varying rates of reintervention associated with ablation, depending on the chosen technology and circumstances under which it is used.
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• Treatment with hysterectomy is effective and permanent; however, there are high rates of morbidity and costs.
5,6

BACKGROUND
• To describe the treatment patterns, healthcare utilization, and medical and productivity costs among commercially insured women initiating menorrhagia treatment with global endometrial ablation (GEA) or hysterectomy -The average age among hysterectomy patients was modestly lower than previous published national averages where regional mean ages ranged from 44.5 to 49.1 years.
STUDY OBJECTIVE
7
• Information on race, socioeconomic status, anthropometrics, and mortality are unavailable.
• As observed in other retrospective claims database analyses, the most completely recorded data are those that affect reimbursement. Hence, it is expected that the capture of expenditures is highly accurate whereas there is a potential for underascertainment of individual comorbidities and indicators of severity.
• Procedure coding is limited in its ability to differentiate specific types of GEA or hysterectomy for more specified analysis. There are documented differences in effectiveness across different GEA approaches.
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• Indirect costs included in this analysis are not exhaustive. For example, absenteeism and STD claims do not include caregiver time, childcare time, long-term disability, or reduced productivity while at work.
• The study population consists of patients with commercial insurance; therefore, the results may not be representative of all patients with menorrhagia, especially those uninsured or covered by Medicaid.
LIMITATIONS
• Hysterectomy was nearly twice as expensive as GEA for menorrhagia treatment in terms of direct medical costs and costs associated with workplace absenteeism and STD.
• Treatment-related complications were more common among hysterectomy patients, matching the results of a recent meta-analysis.
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• Lost productivity represents a significant portion of menorrhagia treatment-related costs, particularly for women undergoing hysterectomy.
• Minimally invasive procedures, like GEA, appear to be an avenue for potential cost savings in the treatment of menorrhagia.
CONCLUSIONS
• Women who received GEA or hysterectomy • Reintervention and adjunctive pharmacotherapy -Reintervention was defined for GEA patients as the receipt of a second GEA procedure or hysterectomy. Reintervention was evaluated for 3 years post-index.
-Adjunctive pharmacotherapy was defined as receipt of LNG-IUS, non-IUS hormonal therapy, or tranexamic acid in the 3 years post-index.
• Direct medical costs -Intervention-related costs included treatment-related costs and complications, medical care utilization and costs in the 30 days following index, and subsequent GYN-related utilization of inpatient and outpatient services for the remainder of the 12-month post-index period.
-All costs were adjusted to 2011 USD.
• Complications -Complications were defined as the presence of cervical occlusion, cervical trauma (including cervical lacerations and hematometra), uterine perforation, bowel perforation, fluid overload, pregnancy, pyometra, senile cervicitis and device complications; a second GEA or hysterectomy within 30 days; or an inpatient stay or ER visit within 2 days of the index procedure (excluding patients with an inpatient index event).
• Indirect costs -Workplace absenteeism and short term disability (STD) claims were available for a subset of patients in the MarketScan Health and Productivity Management Database.
• Absenteeism costs assume a wage constant of $30/hour.
• STD claims assume a wage constant of $30/hour and 8 hours/day with an adjustment factor of 70%. (Table 2) • Treatment-related complications were more common for hysterectomy (36%) than for GEA (15%, P < 0.001). (Table 2) • Treatment initiation and 30-day follow-up costs were higher for hysterectomy ($12,147) than for GEA ($5,837, P < 0.001), as were gynecologic-related costs for remainder of the year ($284 vs. $147, P < 0.001). (Table 2) • Absenteeism costs in the year following treatment initiation were higher for hysterectomy ($7,543) than for GEA ($5,621, P < 0.001). (Table 3) • Hysterectomy patients were 4 times more likely to have an STD claim than GEA patients (84% vs. 21%, P < 0.001) with similar costs per-claim ($6,802 vs. $6,472, P = 0.29), which resulted in higher per-patient STD costs across all patients ($5,744 vs. $1,361, P < 0.001). (Table 3) • The total treatment-related and indirect costs were significantly higher for hysterectomy patients than GEA patients in the year following the index event ($25,718 vs. $12,967, P < 0.001). (Figure 1) 
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